February 14th, 2023 | 15:49 CET
Takeover fever around biotechs - Bayer's reaction, purchase candidates BioNxt and Morphosys?
Table of contents:
At home in Southern Germany, the passionate stock exchange expert has been accompanying the capital markets for about twenty years. With a soft spot for smaller companies, he is constantly on the lookout for exciting investment stories.
Bayer: Stronger focus on drugs?
During JP Morgan's healthcare conference in January, three major companies announced acquisitions in the biotech sector. Pharmaceutical companies AstraZeneca, Ipsen and Chiesi each completed billion-dollar acquisitions. Industry insiders have noticed the fact that biotechs have become the focus of buyers too. "We continue to expect a biotech bull market in 2023, which could evolve into a wave of acquisitions as credit conditions improve," said John Newman, an analyst at Canaccord Genuity. Experts at EY also expect a turnaround after a weak biotech year in 2022. Bayer Group could also set out to buy complementary technology.
It was only recently announced that American Bill Anderson will become Bayer's new CEO. The manager, who has already worked at Genentech, Roche and Biogen, has brought 25 new drugs to market in his career - including a full 15 blockbusters. As the research portal researchanalyst.com speculates in a recently published outline of Anderson's personnel, the pharmaceuticals division at Bayer could once again become the focus of attention in the future. The loser, on the other hand, could be the agricultural business. In order to implement such a transformation, new products with prospects are likely to play a significant role. It would be no surprise if Bayer already had some promising projects on its radar.
BioNxt: Active ingredient patch as an insider tip?
One company that could fit very well into the grid of pharmaceutical companies due to its orientation and size is BioNxt. The Canadians are specialists in innovative drug delivery systems, provide tests for oral health and offer a psychedelics division. BioNxt strikes a chord in the first business segment in particular. Even if the term "innovative dosage forms" sounds a bit cumbersome, the business is catchy in the truest sense of the word: When active ingredients are no longer administered orally, for example, but through patches, this can bring several advantages. From better tolerability to savings because fewer active ingredients are needed, many advantages are conceivable. BioNxt is currently working on medical patches for the Parkinson's drug rotigotine. Last fall, the Company presented convincing studies in which the patches developed 100% by BioNxt were able to compete with an existing drug.
Most recently, BioNxt unveiled a commercialization plan around its patch project, which includes a pilot human clinical trial in the second quarter. The Company also plans to develop capacity for commercial manufacturing of its proprietary patches. The Company emphasizes that BioNxt's platform approach may benefit other projects around drug patches. Market researchers at Research and Markets estimate that the total market for active ingredient patches will reach USD 6.5 billion in 2020. According to Kuick Research, this market volume could grow to USD 20 billion by 2028. On the market, the development of BioNxt has yet to take off. Since the diagnostics business also appears to have good prospects in the short term, savvy investors can take a closer look at the Company.
Morphosys: The big breakthrough has so far failed to materialize
The fact that it is sometimes not at all advantageous for a company to advance numerous projects at the same time is shown by the performance of Morphosys - over the course of a year, the share price has fallen by almost 29%. The Company has an impressively full research pipeline covering cancer, rheumatism and Alzheimer's disease. In addition, Morphosys is considered the market leader in the field of therapeutic antibodies. Although there are repeated rumors of interest from large pharmaceutical companies, and the Company is working with partners such as Incyte on active ingredients such as tafasitamab, the big breakthrough has yet to be achieved. High costs are weighing on the figures, and Morphosys has not yet been able to achieve a breakthrough with an active ingredient. Thanks also to its high cash reserves, Morphosys could move into the focus of larger companies - but this requires convincing clinical results.
The biotech industry is in turmoil - big pharma companies are looking for tomorrow's revenue generators. While Morphosys offers a broad portfolio, companies like BioNxt focus on solutions in niches, such as drug patches. BioNxt's offering can also complement the portfolio of established pharmaceutical companies and create synergies when transferred to their broad product range. It can be worthwhile to stay on the ball, especially with small companies in the biotech sector.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may hold shares or other financial instruments of the aforementioned companies in the future or may bet on rising or falling prices and thus a conflict of interest may arise in the future. The Relevant Persons reserve the right to buy or sell shares or other financial instruments of the Company at any time (hereinafter each a "Transaction"). Transactions may, under certain circumstances, influence the respective price of the shares or other financial instruments of the Company.
In addition, Apaton Finance GmbH is active in the context of the preparation and publication of the reporting in paid contractual relationships.
For this reason, there is a concrete conflict of interest.
The above information on existing conflicts of interest applies to all types and forms of publication used by Apaton Finance GmbH for publications on companies.
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and the like on news.financial. These contents are exclusively for the information of the readers and do not represent any call to action or recommendations, neither explicitly nor implicitly they are to be understood as an assurance of possible price developments. The contents do not replace individual expert investment advice and do not constitute an offer to sell the discussed share(s) or other financial instruments, nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but a journalistic or advertising text. Readers or users who make investment decisions or carry out transactions on the basis of the information provided here do so entirely at their own risk. No contractual relationship is established between Apaton Finance GmbH and its readers or the users of its offers, as our information only refers to the company and not to the investment decision of the reader or user.